MOTS-c is a 16-amino-acid mitochondrial-derived peptide (encoded in mitochondrial 12S rRNA) studied in animal models as an exercise mimetic — activating AMPK, improving insulin sensitivity, and declining with age.
Product definition
What is MOTS-c?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (encoded in mitochondrial 12S rRNA) studied in animal models as an exercise mimetic — activating AMPK, improving insulin sensitivity, and declining with age.
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a 16-amino-acid peptide discovered by Changhan David Lee's group at USC, encoded by a small open reading frame within the 12S rRNA gene of the mitochondrial genome. Unlike all prior research peptides, it is not a nuclear gene product — it is a mitochondria-encoded signaling molecule that translocates from mitochondria to the nucleus and into systemic circulation, functioning as a retrograde signal from the mitochondria to the rest of the organism.
The functional research profile documents AMPK activation as the primary downstream effect in skeletal muscle — the same kinase activated by metformin and physical exercise. MOTS-c-treated rodents show improved glucose tolerance, increased skeletal muscle glucose uptake (GLUT4 translocation), reduced diet-induced obesity, and enhanced physical performance in exercise capacity models. The discovery that plasma MOTS-c rises with exercise and declines with age across multiple mammalian species has made it a central compound in the emerging field of mitochondria-aging research.
Research context
How is MOTS-c described in the research literature?
MOTS-c activates AMPK and the folate-methionine cycle, promoting insulin-independent glucose uptake in skeletal muscle. In rodent studies, MOTS-c administration improves insulin sensitivity, reduces adiposity, and activates metabolic pathways normally engaged by exercise. Plasma MOTS-c declines with age, rises with physical activity — positioning it as a mitochondrial-nuclear metabolic communication signal.
Compound profile
Key facts about MOTS-c
- Class
- Mitochondrial-derived peptide (MDP)
- Encoding
- Mitochondrial 12S rRNA gene — not nuclear genome encoded
- Amino acids
- 16
- Molecular weight
- ~2,174 Da
- Primary mechanism
- AMPK activation, folate-methionine cycle, insulin-independent glucose uptake
- Discovery
- Lee et al., Cell Metabolism, 2015
- Research category
- Mitochondrial biology, aging, exercise mimetic, metabolic disease
- Storage
- Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days
Research areas
What research areas is MOTS-c associated with?
- Only mitochondria-encoded peptide — mechanistically distinct from all nuclear-gene-derived research compounds
- Activates AMPK in skeletal muscle — the same pathway as metformin and exercise, via an insulin-independent mechanism
- Studied as exercise mimetic in rodent models — improves glucose tolerance and metabolic markers in sedentary animals
- Plasma MOTS-c declines with age, rises with exercise — relevant to aging biology and mitochondrial signaling research
- Investigated for visceral adiposity reduction and insulin sensitivity improvement in diet-induced obesity rodent models
- Defines the mitochondrial-derived peptide (MDP) research class — reference compound for mitochondria-nuclear signaling studies
Research audience
Who researches MOTS-c?
MOTS-c is used by researchers in mitochondrial biology, aging science, metabolic disease, AMPK pharmacology, exercise physiology, and insulin resistance research. It is the foundational compound for studying mitochondrial-derived peptide signaling and is particularly relevant for investigators studying how mitochondrial function communicates with systemic metabolism.
Preclinical research overview
What does the preclinical literature say about MOTS-c?
MOTS-c was discovered in 2015 by Changhan David Lee's group at USC and published in Cell Metabolism. The discovery that the mitochondrial genome encodes a secreted peptide that functions as a systemic metabolic regulator was a conceptual advance for mitochondrial biology — prior to this, the mitochondrial genome was assumed to encode only structural components of the oxidative phosphorylation machinery.
Subsequent research has established MOTS-c as the best-characterized member of the MDP class. In rodent obesity models, systemic MOTS-c administration reverses high-fat diet-induced obesity, improves glucose homeostasis, and increases physical exercise capacity — effects attributed to AMPK activation in skeletal muscle and adipose tissue. The folate-methionine cycle activation provides a mechanism for MOTS-c's effects on AMPK independent of direct adenylate kinetics.
Human aging studies have documented age-related decline in plasma MOTS-c levels and inverse correlation between MOTS-c levels and obesity/metabolic syndrome markers, supporting the hypothesis that declining MDP signaling contributes to metabolic aging. Phase I clinical research with MOTS-c is ongoing, making it one of the few mitochondrial-derived peptides with early human data in the pipeline.
Common questions
Frequently asked about MOTS-c
What makes MOTS-c mechanistically different from other metabolic peptides?
Every other research peptide is encoded by the nuclear genome and produced in ribosomes. MOTS-c is encoded in the mitochondrial genome — a 16,569 bp circular genome that encodes only 37 genes total, previously thought to exclusively encode oxidative phosphorylation components. MOTS-c's discovery demonstrated that the mitochondrial genome produces a systemic signaling peptide, which is a mechanistic class distinction with fundamental implications for understanding mitochondria-to-nucleus retrograde communication and aging biology.
How does MOTS-c compare to humanin and other MDPs?
Humanin (HN) was the first characterized MDP, discovered in 2001. MOTS-c is a later discovery with a distinct amino acid sequence and mechanism. Humanin's primary research context is neuroprotection and Alzheimer's disease; MOTS-c's primary context is metabolic regulation and exercise biology. Both decline with age, but they differ in their downstream signaling pathways and tissue distribution. MOTS-c is the most studied MDP for metabolic/aging research; humanin is the reference for neuroprotective MDP research.
Are there any published human data on MOTS-c?
Observational human data exist: plasma MOTS-c levels decline with age in human cross-sectional studies and show inverse correlation with metabolic syndrome markers. Exercise-induced MOTS-c elevation has been documented in human plasma samples. Interventional clinical trials are in early stages as of the current research landscape. Published preclinical rodent data constitutes the bulk of the mechanistic research base.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy